Benzinga•2026-04-21
IDEAYA Biosciences Reveals Late-Breaking Abstract Oral Presentation At ASCO 2026 To Provide Complete Data from Phase 2/3 Registrational Trial Of Darovasertib In Combination With Crizotinib In 1L HLA*A2-Negative Metastatic Uveal MelanomaIDYA — IDEAYA Biosciences Inc
NASDAQ · Biotechnology · Biotechnology
$30.73-7.61%Market cap2.88B
- Latest Close
- $30.73
- 30-Day Move
- -7.6%
- Market Cap
- $2.9B
- Shares Outstanding
- 87,810,000
- P/B Ratio
- 2.96
- ROE
- -11.1%
Analyst consensus: Buy · 25 analysts
NASDAQ:IDYABiotechnology / BiotechnologyDelayed public snapshot
IDEAYA Biosciences Inc
A read-only Alphactor snapshot forIDEAYA Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$30.73
30-Day Move
-7.6%
Market Cap
$2.9B
Shares Outstanding
87,810,000
P/B Ratio
2.96
ROE
-11.1%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$30.73
-7.6%last 90 delayed daily bars
Market cap$2.9B
90D High
$39.28
90D Low
$29.47
Avg Volume
1,097,435
What stands out
Net margin is 16.4%, useful for comparing IDYA against peers in Biotechnology.
IDYA is down 7.6% over the last 30 trading days shown on this page.
Latest operating income is $-159M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$13.42
Rule of 40
2990.8%
Fundamentals snapshot
Latest Close
$30.73
30-Day Move
-7.6%
Market Cap
$2.9B
Shares Outstanding
87,810,000
P/B Ratio
2.96
ROE
-11.1%
ROA
-10.3%
Operating Margin
6.3%
Net Margin
16.4%
Debt / Equity
0
Current Ratio
11.34
Latest Revenue
$219M
Financial statement snapshot
Revenue
$219M
Gross Profit
--
Operating Income
$-159M
Net Income
$-114M
Gross Margin
--
Net Margin
1645.0%
Current Ratio
11.34
Debt / Equity
0.00
Valuation snapshot
Fair Value
$13.42
Upside / Downside
-56.3%
Signal
Overvalued
Implied Growth
--
EV/Rev
$13.42
Growth Assumption
50.0%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$30.73
Composite Fair Value
$13.42
EV/Rev
$13.42
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
19.42
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.63x
Rule of 40
2990.8%
Elite
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $51M | $-63M | $-59M | $-91M |
| 2023-12-31 | $23M | $-134M | $-113M | $-118M |
| 2024-12-31 | $7M | $-327M | $-274M | $-251M |
| 2025-12-31 | $219M | $-159M | $-114M | $-73M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-21
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal MelanomaAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$2M
Sell Value
$0
Buys
1
Sells
0
Buy Value
$2M
Sell Value
$0
Buy/Sell Ratio
1.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-02 | Stein Jeffrey | Buy | 50,000 | $32.96 |
| 2026-01-30 | Bleharski Joshua | A | 170,000 | $0.00 |
| 2026-01-30 | WHITE MICHAEL ANTHONY | A | 190,000 | $0.00 |
| 2026-01-30 | DORMAN STUART | A | 155,000 | $0.00 |
| 2026-01-30 | Snyder Douglas B. | A | 130,000 | $0.00 |
| 2026-01-30 | Ruiz Briseno Andres | A | 80,000 | $0.00 |
| 2026-01-30 | Hata Yujiro S | A | 600,000 | $0.00 |
| 2026-01-30 | Beaupre Darrin | A | 175,000 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SmallCap World Fund Inc | 4,792,824 | 0.05% | 2025-12-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4,166,928 | 0.05% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,630,793 | 0.03% | 2025-12-31 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 2,014,523 | 0.02% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,944,116 | 0.02% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1,704,326 | 0.02% | 2026-03-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1,255,428 | 0.01% | 2026-02-28 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 1,245,000 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-11-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$455M
+0.0%
BlackRock
Filed 2024-05-10
$262M
--
Capital Research Global Investors
Filed 2026-02-11
$183M
-19.4%
Vanguard Group
Filed 2026-01-29
$174M
+2.0%
Geode Capital Management
Filed 2026-02-09
$72M
-3.6%
Analyst consensus?
Rating(?)
4.24
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
25
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.